Dr Reddy’s Labs Q3 Results 2026: PAT falls 14% to Rs 1210 cr, revenue up 4% - Quarterly earnings details

Q3 Results 2026: Major drug maker Dr Reddy’s Laboratories on Wednesday (January 21) reported its financial performance for the third quarter of the current financial year (FY26). The pharma major posted a double-digit decline in profit after tax (PAT) during the quarter. The pharma company's net profit for the quarter fell 14 per cent year-on-year and 16 per cent quarter-on-quarter to Rs 1,210 crore, with a PAT margin of 13.9 per cent. The large-cap pharma company’s revenue stood at Rs 8,727 crore, a 4.4 per cent year-on-year increase, while declining 0.9 per cent sequentially. Growth during the quarter was driven by the core business, excluding the impact of specific products.